Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: A feasibility study of the Dutch Colorectal Cancer Group (DCCG)

Marijnen, C.A.M.; Rutten, H.; Wilt, Hans de; Tesselaar, Margot E.T.; Nuyttens, J.; Remmelzwaal, J.; Punt, Cja; Martijn, Hendrik; Hospers, Geesiena; Cats, Annemieke

doi:10.1200/jco.2008.26.15_suppl.15040

Cited by 17 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other recent studies using molecular targeted drugs are listed in Table 3 and have included phase I, phase II, and random phase II trials. [65][66][67][68][69][70][71][72][73][74][75][76] Some studies have shown pathological complete response rates as high as 32%. Further clinical trials are needed to confi rm the effi cacy of these regimens in the future.…”

Section: Radiotherapy Combined With Molecular Targeted Drugsmentioning

confidence: 98%

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

Watanabe

2008

Int J Clin Oncol

View full text Add to dashboard Cite

Local recurrence is an important factor in determining the outcome of patients after surgery for rectal cancer, and various attempts have been made to reduce the local recurrence rate. Randomized controlled trials have shown that radiotherapy combined with total mesorectal excision can reduce the local recurrence rate in rectal cancer patients who undergo curative surgery. Chemoradiotherapy is more effective in achieving local control than radiotherapy alone, and preoperative chemoradiotherapy is superior to postoperative chemoradiotherapy in terms of adverse events. Recent advances have led to the identification of potential therapeutic targets such as epidermal growth factor receptor, vascular endothelial growth factor, and endothelial receptors. These new agents have been used in combination with conventional chemoradiotherapy, and higher pathological complete response rates have been reported for such combinations in comparison with conventional regimens. With regard to lateral node dissection, a recent study showed that postoperative chemoradiotherapy was more effective in reducing the local recurrence rate than lateral node dissection. As for adjuvant chemotherapy, one randomized controlled trial showed that patients who received uracil and tegafur as adjuvant therapy had significantly prolonged relapse-free survival times and overall survival times. As well, one metaanalysis has shown the efficacy of oral uracil-tegafur as adjuvant chemotherapy for rectal cancer.

show abstract

Section: Radiotherapy Combined With Molecular Targeted Drugsmentioning

confidence: 98%

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

Watanabe

2008

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In a preliminary report of 23 patients with LARC from the Dutch Colorectal Cancer Group [47] bevacizumab (5 mg/kg on days −14, 1, 15, 29) with concurrent capecitabine (825 mg/m 2 twice daily) and radiation (50 Gy in 25 fractions) obtained pCR in 2 out 21 valuable patients. Grade 3 chemoradiation toxicities were experienced by 7 patients (skin = 4, diarrhea = 2, tenesmus = 1).…”

Section: Bevacizumab As Radiosensitizermentioning

confidence: 99%

The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer

Torino

Sarmiento

Gasparini

2013

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Weitere Studien zum neoadjuvanten Einsatz von BevacizumabbeimRektumkarzinomzeigeneinepCR-Ratevon9% [15], 25% [16] und 32% [17]. Eine deutsche Phase-II-Studie mitBevacizumabplusCapecitabin/Oxaliplatinparallelzueiner präoperativenRadiatiowirdderzeitdurchgeführt(Abb.2).…”

Section: Cetuximab Als Teil Der Neoadjuvanten Therapieunclassified

Therapie des Rektumkarzinoms

Rödel

Bruch²,

Hofheinz³

et al. 2010

Onkologie

View full text Add to dashboard Cite

Bei Patienten mit Rektumkarzinom des Stadiums II/III ist die primÄre neoadjuvante Radiochemotherapie (RCT) mit infusionalem 5-Fluorouracil (5-FU) etabliert, denn sie verbessert die lokale Tumorkontrolle. Nach wie vor stellt die hohe Fernmetastasierungsrate ein Problem dar. PrÄliminÄre Daten einer Phase-III-Studie mit Capecitabin versus infusionalem 5-FU zeigen ein besseres Lymphknoten-Downstaging durch die neoadjuvante Therapie mit Capecitabin. Die Hinzunahme von Oxaliplatin konnte hingegen in 2 aktuellen Phase-III-Studien die pathohistologische Vollremissionsrate (pCR-Rate) nicht signifikant verbessern. Ob sich dennoch ein Einfluss auf die Langzeitprognose der Patienten zeigen wird, bleibt abzuwarten. Die Erweiterung einer neoadjuvanten systemischen RCT mit Bevacizumab ist ein Ansatz, der in Phase-I/II-Studien zu vielversprechenden Ergebnissen fÜhrte. Dagegen konnte durch die Hinzunahme von Cetuximab zu einer RCT in den meisten publizierten Untersuchungen keine Verbesserung der pCR-Rate erreicht werden. Die Rolle der adjuvanten Chemotherapie ist umstritten. Die aktuelle S3-Leitlinie empfiehlt die adjuvante Chemotherapie nach neoadjuvanter RCT unabhÄngig vom Tumorstadium, also auch bei Patienten mit kompletter Remission oder UICC (Union internationale contre le cancer)-Stadium I/II. Neuere Studien prÜfen die Induktionschemotherapie vor neoadjuvanter RCT und die Bedeutung der ausschließlichen Chemotherapie ohne RCT bei dafÜr geeigneten Patienten. Eine neue operative Technik ist die erweiterte posteriore perineale Resektion mit Gluteus-maximus-Lappen-Rekonstruktion des Beckenbodens (zylindrische Resektion nach Holm), die zu signifikant mehr CRM (circumferential resection margin)-negativen Tumoren und zu signifikant weniger intraoperativen Perforationen fÜhrt.

show abstract

Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: A feasibility study of the Dutch Colorectal Cancer Group (DCCG)

Cited by 17 publications

References 0 publications

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

Chemoradiotherapy and adjuvant chemotherapy for rectal cancer

The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer

Therapie des Rektumkarzinoms

Contact Info

Product

Resources

About